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A B S T R A C T
Synthetic peptides with cyclic arginine-glycine-aspartate motif (cRGD) play an important role in cell recognition
and cell adhesion. cRGD-decorated soluble polymers and polymeric nanoparticles have been increasingly used
for cell-specific delivery of antitumor drugs. While the significance of cRGD modification for tumor cell-specific
targeting of polymeric carriers is well-accepted, straightforward procedures ensuring the fidelity of cRGD
modification of polymeric systems are still lacking. Herein, we have reported an in-situ polymerization approach
for synthesis of cRGD-end-functionalized well-defined polymers as potential building blocks of targeted drug
delivery systems. A new cRGD peptide functionalized RAFT agent was synthesized as confirmed by MALDI-TOF
and 1H NMR spectroscopy. The ability of this RAFT agent to control polymerizations was then tested using two
different monomers oligoethyleneglycol acrylate and t-butyl methacrylate. The RAFT-controlled character of
polymerizations and the living characteristic of the synthesized polymers were investigated through a series of
kinetic experiments. The cytotoxicity and targeting capability of cRGD-functionalized OEGA polymers were
investigated using cell lines expressing αvβ3 integrins at varying extents.
1. Introduction
Among various targeting peptides, the cyclic arginine-glycine-as-
partate (cRGD) motif plays an important role in cell recognition and cell
adhesion in cancer diagnosis and treatment as it has selective affinity
for αvβ3 integrins that are highly expressed on tumoral endothelial cells
as well as many tumor cells, including osteosarcomas, glioblastomas,
melanomas, and carcinomas of lung and breast [1–15]. Accordingly,
cRGD peptide conjugated polymers and lipids have been widely used
for delivering anti-cancer chemotherapeutics, genes and contrast agents
to tumor cells overexpressing αvβ3 integrin receptors [4,5,9].
RGD-binding site is a composite binding site in integrins made of α
and β subunits. The guanidine functional group of arginine residue in
RGD motif is engaged in a bidentate salt bridge with a highly conserved
aspartic acid residue present in the α subunit of the receptor. The
carboxylate group of aspartic acid residue of RGD peptide interacts with
the metal-ion dependent adhesion site which is located in β subunit of
the receptor [16]. Numerous work has been reported for targeting drugs
to tumors using cRGD peptide [17–25]. cRGD decorated polymeric
micelles, nanoparticles and soluble polymers have been widely used for
targeted delivery of anticancer therapeutics [6–30]. The most common
approach to prepare cRGD-functionalized polymeric systems for tar-
geting tumor cells involves the conjugation of cRGD to pre-made
polymers with functional end-group or to micelle corona [21,31–35].
However in general the post-polymerization conjugation of peptides to
polymers or micelles has the disadvantage of poor conjugation effi-
ciency due to steric hindrance problems and more importantly it
usually yields poorly-defined, heterogeneous systems depending on the
conjugation yields. Practicality of this approach may also be limited as
it requires an excess amount of peptide and tedious purification steps
[36]. In the case of conjugating short targeting peptides such as cRGD
(which consists of 4–5 amino acid residues) to polymers or polymeric
systems (such as micelles), it is common to obtain a mixture of non-
conjugated and conjugated polymers/polymeric systems as it is usually
not possible to separate the peptide-conjugated polymers from the non-
conjugated ones via simple purification techniques due to the short
sequence of the peptide, which leads to poorly-defined drug carriers. All
these disadvantages and limitations affect the targeting efficacy of the
delivery system and also make the establishment of structure-activity
correlations impossible.
In order to improve the quality of targeted drug delivery systems
based on polymers, the controlled radical polymerization (CRP)
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techniques which have proved to improve the conjugation yield, reduce
the heterogeneity in the biomolecule-polymer conjugate and minimize
purification steps [37–41] would be useful. Considering the importance
and common usage of cRGD peptide as a cell-specific targeting moiety
in cancer therapy and diagnosis, we propose an in-situ polymerization/
conjugation approach to synthesize cRGD-functionalized well-defined
polymers as potential building blocks of targeted drug/gene/contrast
agent carrier systems. To the best of our knowledge, an in-situ poly-
merization approach has not been applied to the synthesis of cRGD-
functionalized polymers. The approach utilizes RAFT polymerization
which was successfully applied to the in-situ synthesis of protein-
polymer conjugates [42] as well as polymers with carboxyl [43], hy-
droxyl [44], imidazole [45], acetal [46], biotin ester [47] and sugar
[48] end moieties. Accordingly, a new cRGD peptide functionalized
RAFT agent was synthesized and then tested using two different
monomers oligoethyleneglycol acrylate and t-butyl methacrylate. The
RAFT-controlled character of polymerizations and the living char-
acteristic of the synthesized polymers were demonstrated. The cyto-
toxicity as well as the targeting capability of cRGD-functionalized
polymers were further investigated using cell lines expressing αvβ3 in-
tegrins at varying extents. The results are discussed below.
2. Experimental section
2.1. Synthesis of 4-cyano-4-(ethylsulfanylthiocarbonyl) sulfanyl pentanoic
acid (1)
4-Cyano-4-(ethylsulfanylthiocarbonyl) sulfanyl pentanoic acid was
synthesized according to the procedure shown in Scheme 1. Synthetic
method was adapted from Moad et al. [49]. The crude ECT was isolated
by column chromatography using silica gel as the stationary phase and
60:40 ethyl acetate: hexane as the eluent (% yield, 60%).
1H NMR (CDCl3, δ in ppm): 1.38 (t, SCH2CH3), 1.88 (s, CCNCH3),
2.40–2.70 (m, CH2CH2), 3.33 q (q, SCH2CH3).
2.2. Synthesis of cRGD modified 4-cyano-4-(ethylsulfanylthiocarbonyl)
sulfanyl pentanoic acid
Synthesis of cyclic RGD modified RAFT agent involves a two-step
process.
2.2.1. 4-Cyano-4-ethylsulfanylthiocarbonylsulfanyl-4-methyl-butyric acid
2,5-dioxo-pyrrolidin-1-ylester (active ester) (2)
The first step involves activation of 4-cyano-4-(ethylsulfanylthio-
carbonyl) sulfanyl pentanoic acid (0.19 mmol)) using N,N,-dicyclohex-
ylcarbodiimide (0.28 mmol) and N-hydroxysuccinimide (0.29 mmol) as
activating reagent in dichloromethane (5 ml) as solvent for 10–12 h at
room temperature, reaction progress was monitored by thin layered
chromatography using dichloromethane as the eluent. The dicyclo-
hexylurea (DCU) by-product was filtered off. The filtrate was evapo-
rated to dryness under vacuum to give a crude product, which was then
taken up in 2ml of dichloromethane. The insoluble solid was filtered
off. 5% n-Hexane was then added to the filtrate that still contained
insoluble product (dicyclohexylurea) and stored in freezer overnight
and filtered. The filtrate was concentrated and slurried in diethyl ether
(2 ml) to give the titled product as a yellow solid (0.068 g, Yield: 83%).
1H NMR (DMSO, δ in ppm): 1.27 (t, SCH2CH3), 1.86 (s, CCNCH3),
2.50–2.90 (m, CH2CH2), 2.8 (s, COCH2CH2CO), 3.38 (q, SCH2CH3).
2.2.2. cRGD modified 4-cyano-4-(ethylsulfanylthiocarbonyl) sulfanyl
pentanoic acid (3)
Second step involves the reaction of cRGD with previously prepared
4-cyano-4-ethylsulfanylthiocarbonylsulfanyl-4-methyl-butyric acid 2,5-
dioxo-pyrrolidin-1-yl ester (active ester) in N’N-dimethylformamide
(DMF) (2.5 ml) at 5–25 °C. Briefly, DMF (2.5ml) was added to the so-
lution of 4-cyano-4-ethylsulfanylthiocarbonylsulfanyl-4-methyl-butyric
acid 2,5-dioxo-pyrrolidin-1-yl ester (0.000138mmol), cRGD peptide
(0.000138mmol) in DMF (2.5 ml) was added slowly dropwise over a
period of 10–15min at 5–10 °C. The reaction mass was then warmed to
room temperature and allowed to stir for 12 h. After 12 h, the organic
layer was concentrated up to 1–2 vol stage under high vacuum below
35 °C, slowly added 2ml of diethyl ether and filtered through Buchner
funnel. The crude product was purified by slurry wash with diethyl
ether (2 ml), dichloromethane (5ml) and chilled THF: water (10:1)
mixture (2ml) and vacuum dried. The product was collected as yellow
solid (0.06 g, Yield: 65%) and characterized using mass spectrometry
and NMR. Theoretical mass of cRGD modified RAFT agent is 848.61.
The MS analysis indicated mainly the presence of a compound with
[M+H]+ of 849.8, which confirms well the synthesis of cRGD mod-
ified RAFT agent.
1H NMR (DMSO, δ in ppm): 3.0–3.1 (q, 2H, SCH2CH3), 1.75–1.80 (s,
3H, CCNCH3), 2.0–2.4 (m, 4H, CCNCH3CH2CH2CONH), 1.0–1.30 (t,
3H, SCH2CH3), 1.0–1.25 (m, 2H, NHCOCHCH2CH2CH2CH2NH),
1.25–1.75 (m, 4H, NHCOCHCH2CH2CH2CH2NH), 1.2–1.75 (m, 4H,
CONHCHCH2CH2CH2NHC(NH)NH2), 3.0–3.2 (t, 2H, NHCOC-
HCH2CH2CH2CH2NH), 4.5–4.7 (1H, t, NHCHCH2COOH), 8.0–8.25 (m,
5H, NH backbone), 2.8–3.2 (d, 2H, NHCHCH2COOH), 4.0–4.25 (d,
2H,NHCOCH2NH), 4.25 (1H, t, NHCOCHCH2C6H5), 2.9–3.3 (2H, t,
NHCOCHCH2C6H5), 7.0–7.5 (5H, m, CH2C6H5), 10.6 (1H, s,
NHCHCH2COOH).
2.3. RAFT polymerization of OEG acrylate (OEGA) with cRGD RAFT agent
(4)
A typical polymerization procedure using cRGD modified RAFT
agent is described as follows:
OEGA, cRGD modified RAFT agent and 2,2′-azobisisobutyronitrile
(AIBN) as radical initiator were dissolved in N, N-dimethyl acetamide
(DMAc). Briefly, OEG acrylate (0.18mmol), cRGD modified RAFT agent
(0.006mmol) and AIBN (0.0015mmol) were mixed in DMAc (0.9ml)
in a glass vial. Monomer: RAFT agent: initiator mol ratio was 30:1:0.25
with a fixed monomer concentration of 0.20M. The mixture was de-
gassed with nitrogen gas in an ice bath for 30min. The flask was then
immersed in an oil bath at 65 °C. After 6 h, the polymerization was
terminated by placing the flask in an ice bath for 5min and then ex-
posing it to air. A portion of polymerization mixture was dried and
analyzed by 1H NMR spectroscopy to determine monomer conversion.
Monomer conversions were determined by comparing the area of the
vinyl protons (δ ∼ 5.4–6.3 ppm (3H)) to the area of the OEGA char-
acteristic protons (δ ∼ 4,3 ppm, (2H)).
The polymer was precipitated in n-hexane and centrifuged at
3000 rpm for 5min, followed by two subsequent precipitations into n-
hexane. The solvent was decanted and the polymer was dried in a va-
cuum oven for 2 h. The number average molecular weight (Mn) and
molecular weight distribution (PDI) were determined by GPC using
DMAc as the mobile phase.
2.4. RAFT polymerization of t-butyl methacrylate with cRGD RAFT agent.
A typical polymerization procedure using cRGD modified RAFT
agent is described as follows: t-butyl methacrylate, cRGD modified
RAFT agent and AIBN were dissolved in DMAc. Briefly, t-butyl me-
thacrylate (1 mmol), cRGD modified RAFT agent (0.0125mmol) and
AIBN (0.003mmol) were mixed in DMAc (1.0ml) in a glass vial. The
monomer: RAFT agent: initiator mol ratio was 80:1:0.25 at a monomer
concentration of 1.0 M. The mixture was degassed with nitrogen gas in
an ice bath for 30min. The flask was then immersed in an oil bath at
65 °C. The samples were taken at different time points, and poly-
merization was terminated by placing the flask in an ice bath for 5min
and then exposing it to air. A portion of polymerization mixture was
dried and analyzed by 1H NMR spectroscopy to determine monomer
conversion. The polymer was precipitated in methanol/water mixture
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and centrifuged at 3000 rpm for 5min followed by two subsequent
precipitations into methanol/water mixture. The solvent was decanted
and the polymer was dried in a vacuum oven for 2 h. Mn and PDI were
determined by GPC using DMAc as the mobile phase.
2.5. Chain-extension polymerization of poly(OEGA) macroRAFT agent
with OEGA.
The livingness of OEGA polymers synthesized by cRGD RAFT agent
was shown by chain extension polymerization of poly(OEGA)
macroRAFT agent with OEG acrylate monomer. Synthesis of block
Scheme 1. Synthesis of 4-cyano-4-(ethylsulfanylthiocarbonyl) sulfanyl pentanoic acid (1), 4-cyano-4-ethylsulfanylthiocarbonylsulfanyl-4-methyl-butyric acid 2,5-
dioxo-pyrrolidin-1-yl ester (2), cRGD modified RAFT agent (3), cRGD terminated poly(OEGA) (4), cRGD terminated poly (t-BMA) (5).
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copolymer was carried out using the following procedure:
[OEGA]0:[poly(OEGA) Macro RAFT agent Mn:4300]0:[AIBN]0 ratio
of 30:1:0.25 was used. Briefly, OEGA (175mg, 0.365mmol), poly
(OEGA) macro RAFT agent Mn: 4300 (52mg, 0.0121mmol), AIBN
(0.5 mg, 0.0030mmol) and DMAc (1.4ml) were placed in a glass vial
equipped with a magnetic stirrer bar and capped with a rubber septum.
The reaction mixture was deoxygenated for 25min at 0 °C by purging
with N2. The deoxygenated and sealed reaction vessel was placed into a
pre-heated oil bath at 65 °C and the samples were taken at different
time points. The resulting mixture was then allowed to cool to 0 °C for
about 15min and exposed to air to terminate polymerization. The
monomer conversion was determined by 1H NMR. The polymer was
purified by first precipitating into n-hexane, followed by two sub-
sequent precipitations into n-hexane. The product was then placed in a
vacuum oven for 2 h. The final product was analyzed by 1H NMR and
GPC. Mn and PDI were determined by GPC using DMAc as the mobile
phase.
2.6. Determination of in vitro cytotoxicity of cRGD terminated poly(OEGA)
Prior to the cytotoxic assays, the thiocarbonylthio RAFT end-group
of cRGD-terminated poly(OEGA) was removed in order to avoid pos-
sible cytotoxicity of this active group [50]. To remove the RAFT end
group, protocols well known in literature have been performed [51,52].
Briefly cRGD-terminated poly(OEGA) (Mn 6700 g/mol, PDI:1.2,
0.0029mmol) dissolved in methanol was reacted with hexylamine
(0.118mmol) and triethylamine (0.118mmol) in the presence of OEGA
monomer (0.0089mmol). The mixture was stirred for 16 h. The reac-
tion completion was monitored by a UV–Vis spectrophotometer by
scanning the absorbance in the range between 200 nm and 800 nm.
After reaction time, methanol was removed by vacuum evaporation.
The polymer was then precipitated in cold n-hexane (2 times) and dried
under vacuum. The polymer was further purified by dialysis against
water using a dialysis tubing with a molecular weight cutoff of 3000 Da
for four days. The resultant polymer was then dried using a freeze-drier.
For the comparison, poly(OEGA) synthesized using ECT RAFT agent
without cRGD modification (Mn 6200 g/mol, PDI: 1.24) was also ami-
nolyzed using the same above procedure. The effect of both polymers
on the viability of BEAS-2B (human bronchial epithelium) and A549
(human lung adenocarcinoma epithelial) cells was determined by a 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)
Cell Viability assay [53]. The assay measures the ability of living cells to
reduce a tetrazolium dye, MTT to its insoluble formazan giving a purple
color.
In cell viability experiments, BEAS-2B (human bronchial epithe-
lium) and A549 (human lung adenocarcinoma epithelial) cell lines with
passage number 3–10 were seeded a day prior to sample exposure at
104 cells/well (96 well-plate) in DMEM culture medium containing
10% FBS. Polymer sample stocks (cRGD terminated polymer and the
polymer without cRGD) were prepared by dissolving in PBS at pre-
determined concentrations. 5 µl of polymer stocks in PBS were added to
the wells in triplicate. 5 µl of only PBS was also added into wells for
positive control experiments. The cells were incubated at 37 °C, 5% CO2
for 24 or 72 h. Following the incubation, the viability of the cell was
determined by MTT Cell Viability assay. MTT dye was added to wells
according to manufacturer’s protocol. The plates were incubated at
37 °C for 3 h in the dark atmosphere. After the incubation the well
plates were centrifuged at 1800 rpm for 10min. Supernatants were
removed by pouring and the crystals were dissolved in DMSO (100 µl).
Metabolic activity was detected by measuring the absorbance at 570 nm
using a microplate spectrophotometer (Varioskan Flash, Thermo
Electron Corporation, Finland). The cell viability (%) was calculated
relative to the positive control (cells not treated with polymers) ac-
cording to Eq. (1)
=
−
−
×Cell viability(%)
A A
A A
100cell sample blank
positive control blank (1)
2.7. Cell uptake by flow cytometry
Uptake of cRGD-terminated poly(OEGA) (Mn: 6700 g/mol, PDI: 1.2)
and poly(OEGA) without cRGD (Mn: 6200 g/mol, PDI: 1.2) by BEAS-2B
(human bronchial epithelium) and A549 (human lung adenocarcinoma
epithelial) cells was investigated using a flow cytometry (BD
FACSCantoTM A Flow Cytometer, BD Biosciences, San Jose, USA).
Prior to the cell uptake experiment, cRGD-terminated polymer and
poly(OEGA) without cRGD were labeled with Oregon Green maleimide
488 according to manufacturer’s protocol. Firstly, Oregon Green mal-
eimide 488 (5mg, 1.08×10−5 mol) was dissolved in DMF (108 μl) to
have a stock dye solution of 100mM. The dye solution (24.5 μl,
0,25×10−5 mol) was added to thiol and cRGD-terminated polymer
solution after aminolysis (Mn: 6700 g/mol, PDI:1.2) in phosphate buffer
(0.1M, 500 μl, 0.05×10−5 mol). TCEP (0.02M, 2.8 mg,
1× 10−5 mol) dissolved in phosphate buffer solution at pH 7.1 was
also added to the reaction mixture. The reaction solution was purged
with nitrogen for 10min and gently shaken overnight at 37 °C. The
product was then dialyzed against water using a membrane with a MW
cutoff of 3500 Da for 4 days and finally freeze-dried. The degree of la-
belling was determined via UV–Vis spectroscopy (Perkin Elmer Lambda
25 UV/Vis Spectrometer).
As a control, poly(OEGA) without cRGD functionalization was also
labelled with Oregon Green maleimide 488 using the same procedure
for comparison.
BEAS-2B and A549 cells (105 cells/500 µl per well) were seeded in
24 well-plates and incubated in a humidified atmosphere (37 °C, 5%
CO2) for 24 h. After 24 h, Oregon Green labelled polymers with and
without cRGD (dissolved in PBS) were added into wells (30 μl) to yield
a final polymer concentration of 20 μM. The cells and polymers were
incubated for 30min or 60min at 37 °C. Each treatment was performed
in triplicate. At the end of incubation, medium was collected and the
wells were washed with cold PBS. The cells were harvested by trypsi-
nization and collected cells were centrifuged for 5min. Supernatant was
removed and pellet was resuspended with 200 μl PBS and transferred to
flow cytometry tubes for analysis. Data from 10,000 events were col-
lected per sample via flow cytometry and analysed by using FacsDiva
V.5.0.3 software. Solid state 488 laser was used for excitation and 530/
30 filter configuration for detection of Oregon Green. The experiments
were performed in triplicate. Each experiment was repeated twice.
Mean values and standard deviations (n=6) were determined and
presented in the corresponding results/graph. Statistical analysis (t-test)
was performed to evaluate the significance of the differences in results
(**P < 0.01, ***P < 0.001).
3. Results and discussions
To in-situ synthesize cRGD-end-functionalized well-defined poly-
mers via RAFT polymerization, a new RAFT agent containing cRGD
peptide was first synthesized (Scheme 1). Considering the basic char-
acter of cRGD peptide, 4-cyano-4-(ethylthiocarbonothioylthio) penta-
noic acid (ECT) was selected as a suitable chain transfer agent (CTA) as
it is relatively more resistant to hydrolysis and aminolysis. This RAFT
agent is basically different than the other bulk RAFT agents which have
large Z-groups such as dodecyl and phenyl. The presence of alkyl group
at Z-group of the RAFT agent controls the hydrolysis and aminolysis
during modification with cRGD peptide. Consequently, ECT RAFT agent
was successfully synthesized according to method given by Moad et al.
[49] (Fig. S1) (Supporting Information, SI).
Synthesis of cRGD modified RAFT agent involves a two-step process.
The first step is the activation of carboxylic acid of ECT RAFT agent
using DCC/NHS chemistry [54]. The direct conversion of a carboxylic
H. Thankappan et al. European Polymer Journal 103 (2018) 421–432
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acid functional RAFT agent to a cRGD modified RAFT agent is difficult
because cRGD contains basic amine group which converts carboxylic
acids to their highly unreactive carboxylates. In DCC/NHS reaction, the
carboxylic acid present in the RAFT agent adds to the DCC molecule to
form O-acylisourea intermediate. Irreversible rearrangement of the de-
sired, activated intermediate O-acylisourea to the non-reactive N-acy-
lurea is suppressed by reacting O-acylisourea intermediate with NHS
molecule to form an active ester which is a good leaving group. The
active ester can then be displaced by cRGD amine during nucleophilic
substitution. After active ester formation, the dicyclohexylurea (DCU)
by-product was filtered off and slurried by diethyl ether. The product
was then characterized using 1HNMR spectroscopy as shown in Fig. 1.
The appearance of a broad peak at 2.8 ppm corresponds to NHS moiety
[56] indicating the formation of a 4-cyano-4-ethylsulfanylthiocarbo-
nylsulfanyl-4-methyl-butyric acid 2,5-dioxo-pyrrolidin-1-yl ester (ac-
tive ester).
The second step involves the reaction of NHS ester of ECT RAFT
agent with the lysine amine group of cRGD peptide. The product
(theoretical mass: 848.6 g/mol) was characterized using 1H NMR and
mass spectroscopies. The major peak in the mass spectrum (Fig. 2) at an
m/z ratio of 849.80 revealed the covalent conjugation of the cRGD
peptide to the RAFT agent via the primary amine side chain group of
the cRGD peptide and acid group of RAFT agent’s “R” group. The
presence of characteristic peaks of cRGD and RAFT agent in the NMR
spectrum shown in Fig. 3 indicated the successful conjugation of cRGD
peptide with the RAFT agent.
Trithiocarbonate RAFT agents are known to have reasonable control
over polymerizations of both acrylates and methacrylates. Therefore
two different monomers, an acrylate and methacrylate, which are both
relevant to biological applications have been chosen as model mono-
mers to show the ability of the new RAFT agent to control poly-
merizations of both mono- and di-substituted olefinic monomers. The
acrylate-based monomer OEGA was selected since OEGA polymers have
been commonly used in different biotechnological applications [55,56].
Similarly, a methacrylate monomer, t-BMA was also used as the poly-
mers of t-BMA can be converted via acid-catalyzed hydrolysis to me-
thacrylic acid polymers which are commonly used in biomedical ap-
plications such as drug delivery [46,57].
Oligoethylene glycol acrylate (OEGA) monomer was first poly-
merized using cRGD modified RAFT agent. The kinetics of RAFT
polymerization was investigated by varying polymerization time at a
monomer: RAFT: initiator mol ratio of 30:1:0.25 and a monomer con-
centration of 0.20M. Similar experiments were also performed for
RAFT polymerization of t-butyl methacrylate (t-BMA) at a monomer:
RAFT: initiator ratio of 80:1:0.25 and a monomer concentration of
1.0 M. The results are shown in Table S1 and Fig. S2 (SI), and Fig. 4a
and b.
As the monomer conversion increases, the number average mole-
cular weight (Mn) of the polymers increases linearly (Fig. 4b). Similarly,
ln ([M0]/[M]) (first order) versus time plot showed a linear relation
(Fig. 4a), which indicates well the RAFT-controlled polymerization
mechanism of OEGA monomer [58,59]. Relatively narrow molecular
weight distribution (PDI≤ 1.26 up to 60% monomer conversion) of
poly(OEGA)s against calculated conversion values were also obtained
(Fig. 4b). The kinetics results were similar with t-BMA polymerizations
(Fig. 4a and b). Slightly higher PDI values (PDI≤ 1.35 up to 81%
monomer conversion) obtained in the case of t-BMA polymerizations,
can be explained on the basis of increase in steric hindrance making it
difficult for the bulky tertiary propagating radical generated from t-
BMA to add to the C]S of the RAFT agent [60]. The apparent propa-
gation rate constant (kapp) of polymerizations was 0.018 h−1 and
0.061 h−1 for OEGA and t-BMA, respectively, indicating faster poly-
merization reaction of t-BMA when compared with OEGA under the
polymerization conditions used. In accordance with this finding, the ln
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Fig. 1. 1HNMR spectrum of 4-cyano-4-ethylsulfanylthiocarbonylsulfanyl-4-methyl-butyric acid 2,5-dioxo-pyrrolidin-1-yl ester (NHS ester of ECT RAFT agent) (in
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([M0]/[M]) vs. time plot of t-BMA does not intersect with the origin,
which might be due to the slower fragmentation rate of the RAFT agent
with respect to the polymerization rate of t-BMA.
Representative 1H NMR spectra of purified cRGD terminated poly
(OEGA) (conversion: 53%, Mn, GPC: 6700 g/mol, PDI: 1.21) and cRGD
terminated poly (t-BMA) (conversion: 66%, Mn, GPC: 7750 g/mol, PDI:
1.24) are given in Fig. 5a and b. The spectra show all the signals ex-
pected for the polymer structures, and the signal at 7.1–7.3 ppm
Fig. 2. Mass spectrum of cRGD modified 4-cyano-4-(ethylsulfanylthiocarbonyl) sulfanyl pentanoic acid (cRGD RAFT agent).
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corresponding to the aromatic group [32] of cRGD proving the suc-
cessful synthesis of cRGD functionalized polymers.
The living nature of cRGD-ended polymers was further verified by
chain extension of poly(OEGA) (Mn: 4300 g/mol and PDI: 1.13 by GPC)
with OEGA monomer using a [OEGA]0:[ poly(OEGA) Macro RAFT
Agent]0:[AIBN]0 mol ratio of 30:1:0.25 at a monomer concentration of
0.26M. The polymerization results are shown in Table S2 (SI). ln
([M0]/[M]) (first order) versus time plot showed a linear relation
(Fig. 4c). Also, as the monomer conversion increases, Mn of the poly-
mers increases linearly (Fig. 4d). kapp for chain extension polymeriza-
tion was found to be 0.039 h−1. Since the initial monomer and initiator
concentrations were higher in chain extension polymerizations when
compared with homopolymerization, a higher kapp value is expected.
All these indicate well the RAFT-controlled chain extension poly-
merization mechanism [58,59]. Fig. 4d shows narrow molecular weight
distribution of the block copolymers against calculated conversion va-
lues. The increase in PDI (∼1.13 to 1.41) is expected due to the poly-
dispersity of macroRAFT agent and termination reactions at higher
monomer conversions. These results show that the polymer chains
synthesized using new cRGD-functional RAFT agent had a living char-
acter and the ability to control over copolymerization.
Before performing the cytotoxicity assays, the trithiocarbonate
RAFT end group of cRGD terminated poly(OEGA) was removed as this
reactive group might possess toxic effects on living cells [50]. The RAFT
end-group was cleaved in the presence of hexylamine, triethylamine
and OEGA monomer, following a procedure reported previously in the
literature [51,52]. The UV–Vis spectra after aminolysis are shown in
Fig. S3 (SI), which revealed that the living trithiocarbonate end-group
was effectively removed.
The cRGD terminated poly(OEGA) (Mn: 6700 g/mol) and a control
polymer, poly(OEGA) without cRGD end-group (Mn: 6200 g/mol) at
varying concentrations (20 μM, 10 μM, 5 μM, 2.5 μM and 1.25 μM) were
incubated with A549 (human lung adenocarcinoma epithelial) or BEAS-
2B (human bronchial epithelium) cells for 24 and 72 h. The viability of
A549 and BEAS-2B cells after incubation with the polymers (for 24 h
and 72 h) was determined via MTT assay. The results shown in Fig. 6a
and b indicated that cRGD terminated polymer and its counterpart
without cRGD did not have any cytotoxic effect on A549 and BEAS cells
at all concentrations after incubation for 24 h or 72 h. The cell viability
was higher than 85% at all conditions tested. This result showed that
the conjugation of cRGD peptide to the OEGA polymer did not alter the
nontoxic nature of the OEGA polymer.
To investigate the targeted uptake of cRGD-functionalized poly
(OEGA) by cells, cRGD-functionalized poly(OEGA) and its counterpart
polymer without cRGD end-group were labelled with Oregon Green®
488 Maleimide. Before performing labelling, the trithiocarbonate RAFT
end group of cRGD-terminated poly(OEGA) (Mn: 6700 g/mol) and its
counterpart polymer without cRGD end-group (Mn: 6200 g/mol) were
aminolyzed and conjugated with Oregon Green® 488 Maleimide in the
presence of TCEP and phosphate buffer.
The fluorophore number per polymer chain (mol of OG/mol of
polymer) was determined using UV–Vis spectroscopy at 491 nm (the
extinction coefficient of OG at 491 nm: 81 000M−1 cm−1) (Fig. 7).
Based on the absorbance values of polymer solutions at 491 nm, the
extinction coefficient of the dye, and the polymer molar concentrations
used in the measurements, the degree of labelling was calculated ac-
cording to Beer-Lambert Law (Fig. 7 and Table S3 (SI)) giving in Eq. (2)
considering all the dilutions made during measurements:
= × ×εAbs concentration of dye path lengthlabelled polymers (2)
where Abs is the absorbance of the polymer solution at 491 nm, ε is
the extinction coefficient of the dye at 491 nm (81,000M−1 cm−1 ac-
cording to the manufacturer).
The cell uptake of OG-labelled polymers (20 µM) after incubation
with A549 and BEAS cells for 30min or 60min was investigated using
flow cytometry that enabled quantitative analysis of fluor-
escence–associated cells. The flow cytometry plots and % of cell uptake
results were shown in Fig. 8a and b. The % cell uptake was determined
after normalizing the flow cytometry data considering the labeling
degree of polymers.
Fig. 4. (a) ln ([M0]/[M]) versus polymerization time graph, and (b) Mn (GPC) and PDI (GPC) versus conversion (by NMR) graph for homopolymerizations of OEGA
and t-BMA using cRGD modified RAFT agent, in which monomer: RAFT agent: initiator mol ratio ([M]/[R]/[I]) was 30/1/0.25 and 80/1/0.25, respectively. (c) ln
([M0]/[M]) versus polymerization time graph, and (d) Mn (GPC) and PDI versus conversion (NMR) graph for chain extension of poly(OEGA) macroRAFT agent with
OEGA monomer ([OEGA]0:[poly(OEGA) Macro RAFT agent Mn:4300]0:[AIBN]0 was 30/1/0.25).
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It has been reported in the literature that the peptides and proteins
containing RGD motifs, either in linear or cyclic form, recognize αvβ3
integrins and that this recognition can be used to target drugs to tumor
cells [61]. Different cell lines express varying integrin proteins at dif-
ferent extents while cancer cells usually overexpress them [62–65].
Lung cancer cells are among the cancer cells overexpressing αvβ3
integrin receptors [62,65]. Accordingly, we have utilized A549 (human
lung adenocarcinoma epithelial) cell line as a model cell line over-
expressing RGD-binding integrin receptors along with human bronchial
epithelium BEAS-2B cells [63–65]. The uptake of cRGD terminated poly
(OEGA) by A549 and BEAS-2B cells was investigated and compared to
its non-RGD counterpart. For both polymers, time-dependent increase
Fig. 5. 1H NMR spectra of purified cRGD terminated (a) poly(OEGA) (conversion: 53%, Mn,GPC: 6700 g/mol, PDI: 1.21) in DMSO-d6 and (b) poly(t-BMA) (con-
version= 66%, Mn,GPC: 7750 g/mol, PDI: 1.24) in methanol‑d4.
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in uptake was observed (Fig. 8). According to the statistically analyzed
data (t-test, n= 6, **P < 0.01, ***P < 0.001), the percentage cell
uptake of cRGD terminated poly(OEGA) was significantly higher for
both cell lines and incubation periods compared to poly(OEGA) without
cRGD end-group.
Compared to the non-cRGD counterpart, the cRGD modified
polymer was taken up by A549 cells between 1.5 and 2.1-fold excess at
two different time points tested, indicating that the RGD motif has the
ability to recognize targeted integrin αvβ3 receptors overexpressed on
the cancer cells. Indeed, after 30min and 60min incubations, the per-
centage of A549 cancer cells taking up cRGD terminated OEGA polymer
was around 22.5% and 49.6% while the uptake of non-cRGD polymer
by the same cells was 10.6% and 33.6%, respectively. The difference
between the uptake of cRGD-terminated and non-cRGD polymer by
A549 cells was found to be significantly different according to the
statistical analysis. On the other hand, BEAS-2B cells took up cRGD
modified polymer between 4.6- and 2.2-fold excess at 30min and
60min incubations when compared with the non-cRGD polymer up-
take, also suggesting the role of integrin receptors in the uptake cRGD
modified polymer by BEAS-2B cells. However, the total polymer uptake
of BEAS-2B cells was significantly less than that of A549 cells, attrib-
uted to the increased metabolic activity of cancer cells. In accordance
with the higher metabolic activity of A549 cells, the cRGD-terminated
and non-cRGD poly(OEGA) showed approximately 2.6- and 4.7-fold
higher uptake, respectively, in A549 cancer cells as compared to BEAS-
2B cells. Nevertheless, all the results suggest that the cRGD terminated
polymer, when compared with the non-cRGD counterpart, show higher
and accelerated cellular uptake in lung cancer cells and bronchial
Fig. 6. (a) Viability of A549 cells after incubation with the polymers with cRGD (Mn: 6700 g/mol) and without cRGD end-group (Mn: 6200 g/mol) for 24 h and 72 h.
(b) Viability of BEAS-2B cells after incubation with the polymers with cRGD (Mn: 6700 g/mol) and without cRGD end-group (Mn: 6200 g/mol) for 24 h and 72 h.
Control is the cells with no treatment.
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Fig. 7. UV–vis spectra of Oregon Green® labelled poly(OEGA) with and without cRGD end-group (Mn: 6700 g/mol, PDI: 1.27; Mn: 6200 g/mol, PDI: 1.24, respec-
tively). The concentration of both polymers was 45 µM during UV–Vis spectroscopy measurement.
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epithelium cells, potentially due to the binding of cRGD moiety on the
polymers to the surface integrin receptors [65].
4. Conclusions
In summary, we have reported the direct synthesis of cRGD-func-
tionalized polymers for the first time and quantitatively showed the
targeting potential of these well-defined polymers. The method
Fig. 8. (a) Representative flow cytometry plots for A549 and BEAS-2B cell lines taken after 30 and 60min incubation periods. Average percentages and standard
deviations (n= 6) are presented in the figure. (b) The percent uptake of the polymers with cRGD-(Mn: 6700 g/mol) and without cRGD-(Mn: 6200 g/mol) end-group
by A549 and BEAS-2B cells. Incubation time was 30min or 60min. Data were statistically analyzed using t-test (n=6, **P < 0.01, ***P < 0.001).
H. Thankappan et al. European Polymer Journal 103 (2018) 421–432
430
presented here can be easily applied to other acrylate/methacrylate
monomers to obtain better building blocks for potential targeted drug
delivery systems and offer an effective route to design and synthesis of
targeted drug delivery systems for anticancer therapeutics.
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